Lay Summaries

Making clinical trial results accessible and understandable for all

We are committed to ensuring that all our published research is freely available to everyone. We work closely with the patient community to provide summaries of key clinical studies sponsored by Ipsen in easy-to-understand language, so they are not just available, but accessible to all. 

RARE DISEASE

RARE DISEASE

A Phase II study of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)

A Study to Learn about the Effects of Palovarotene in People with Fibrodysplasia Ossificans Progressiva (FOP)

RARE DISEASE

RARE DISEASE

Elafibranor food effect study

A Study to Learn About the Effect of Food on the Levels of Elafibranor in the Blood of Healthy Volunteers

ONCOLOGY

ONCOLOGY

Neuroendocrine tumours – Phase III CLARINET study

A study on the effectiveness of the treatment for patients with non-functioning neuroendocrine tumours of the pancreas, intestines or unknown origin.  

NEUROSCIENCE

NEUROSCIENCE

Phase III ENGAGE study

A study to evaluate the effects of the treatment in patients living with spastic hemiparesis in combination with a prescribed personal rehabilitation program. 

RARE DISEASE

RARE DISEASE

Fibrodysplasia Ossificans Progressive (FOP) – Burden of Illness study

A study to evaluate the impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members. 

NEUROSCIENCE

NEUROSCIENCE

Phase I – Comparative Study of Muscle Action Potential effects

A study comparing the muscle action potential effects in the foot muscle in healthy male volunteers

RARE DISEASE

RARE DISEASE

Primary Billiary Cholangitis – Phase III ELATIVE study

A study to evaluate the efficacy and safety of elafibranor in adult patients with PBC with an inadequate response or intolerance to UDCA.

RARE DISEASE

RARE DISEASE

A study comparing elafibranor in healthy Japanese and non-Asian volunteers

A study in healthy Japanese and non-Asian volunteers to understand what happens to elafibranor in the body when taken by Japanese people compared to non-Asian people.

ONCOLOGY

ONCOLOGY

Effect of CYP3A4 booster and blockers on tazemetostat in advanced cancer

A study to learn about the effect of strong CYP3A4 boosters or blockers on blood levels of tazemetostat (EPZ-6438) in patients with advanced cancer

Contact